UK Valproate Restrictions in Men Justified? New Data
A large Danish cohort study showed no significant increase in neurodevelopmental disorders (NDDs) among children fathered by men taking valproate during spermatogenesis, challenging earlier safety concerns and current UK restrictions on valproate use in men.
As previously reported by Medscape Medical News , the decision to restrict the drug in women and in men younger than 55 years was made in January 2024, after the UK Medicines and Healthcare products Regulatory Agency issued new guidance on the drug's use.
'Paternal exposure to antiseizure medication in association with conception is unlikely to pose any major risk for the offspring,' the investigators led by Jakob Christensen, DrMedSci, consultant neurologist at Aarhus University Hospital and professor at Aarhus University, Aarhus, Denmark, noted.
The study was published online on May 22 in JAMA Network Open .
Unnecessary Precaution?
In the US and Europe, there is strong guidance about avoiding valproate in pregnant women and women of childbearing age due to an elevated risk for birth defects and other developmental problems.
In January 2024, the European Medicines Agency's (EMA's) safety committee (Pharmacovigilance Risk Assessment Committee [PRAC]) expanded precautionary measures on valproate use to men considering fatherhood. The advisory was fueled largely by an observational study by the contract research organization IQVIA.
The study showed that about 5 out of 100 children had an NDD when born to fathers taking valproate during the 3 months before conception compared with about 3 out of 100 when born to fathers treated with lamotrigine or levetiracetam.
Last summer, Christensen and colleagues were unable to replicate the IQVIA results in a study using a subset of the same IQVIA data. However, at the time, only limited information about the IQVIA study was publicly available.
Once additional information from the IQVIA study became available, the researchers tried again to replicate the findings, aligning their methods more closely with the IQVIA study.
Despite using the same methodology and incorporating additional data, they were still unable to replicate the IQVIA findings. Their conclusion remained unchanged — there was no statistically significant increased risk for NDDs.
Specifically, among 961 children exposed to paternal valproate monotherapy and 1401 exposed to lamotrigine or levetiracetam, there was no significant increase in risk for NDDs (adjusted hazard ratio [aHR], 1.02; 95% CI, 0.67-1.54).
'This finding remained robust across analyses of specific NDDs, analyses of valproate dose, analyses accounting for time trends, analyses allowing for polytherapy, analyses expanding the definition of NDDs, analyses restricted to fathers with epilepsy, and analyses with a restricted exposure window,' Christensen and colleagues reported.
Restricting analyses to fathers with epilepsy of unknown cause yielded a higher risk (aHR, 2.48; 95% CI, 1.13-5.44), but this association was no longer significant in analyses matched on birth year (aHR, 2.33; 95% CI, 1.00-5.44).
Additional sensitivity analyses (restricting exposure window, excluding children with epilepsy or maternal epilepsy, and accounting for polytherapy) consistently showed no elevated risk for NDDs associated with paternal valproate exposure.
'We've examined this issue from many angles and still find no evidence supporting the concern behind EMA's recommendations,' Christensen said in a news release.
Will the EMA Reconsider?
Reached for comment, Aatif Husain, MD, epileptologist, neurologist, and sleep medicine specialist at DukeHealth, Durham, North Carolina, said, 'There seems to be a fair amount of literature' suggesting no increased risk for NDDs in children whose fathers use valproate.
'A recent systematic review that included 10 other studies came to this same conclusion,' said Husain, who wasn't involved in the Danish study.
Taken together, the data 'would probably move EMA to relook at their guidance to see if it needs to be modified,' he said.
Medscape Medical News reached out to the EMA press office for comment and received the following response.
'As with every medicine authorized in the EU, EMA continues monitoring and supervising the safety of these medicines. This includes monitoring information from various sources, such as spontaneous reports, clinical studies, scientific literature, and management of safety signals, which consists of a set of activities to determine whether there are new risks associated with an active substance or a medicine or whether known risks have changed. Should there be any updates, EMA will communicate them via the PRAC Highlights.'
Husain told Medscape Medical News that neither the FDA nor the American Epilepsy Society has issued guidance on valproate use in men 'because the data has not been strong enough.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Biking might help lower risk of dementia
Want to reduce your risk of dementia and Alzheimer's disease? Get on your bike and ride, a new study recommends. Biking regularly for transportation appears to lower risk of dementia by 19% and Alzheimer's by 22%, according to results published Tuesday in JAMA Network Open. The results also suggest that cycling might even help increase the size of a brain region important for memory, researchers noted. "Cycling is a moderate- to high-intensity workout, and also requires balance," said Dr. Liron Sinvani, director of geriatric services at Northwell Health in Manhasset, N.Y., who reviewed the findings. "It requires more complex brain function than walking, which is why maybe it was a better reducer of dementia risk." "It's not about just doing exercise and making that part of your routine, but thinking about the way you live your life," she added in a news release. "So instead of having to drive somewhere, taking that bike and using active travel modes to get around as part of your lifestyle becomes very important." For the study, researchers analyzed data on nearly 480,000 people participating in the UK Biobank, a long-term health study of people living in England, Scotland and Wales. As part of the study, participants noted the forms of transport they used most often to get about, not including travel to and from work. During an average follow-up of 13 years, more than 8,800 participants developed dementia and nearly 4,000 developed Alzheimer's. Results showed a lower risk for dementia and Alzheimer's among those who cycled or included cycling among other forms of travel like walking, driving or using public transportation. "Our findings suggest that promoting active travel strategies, particularly cycling, may be associated with lower dementia risk among middle-aged and older adults, which carries substantial public health benefits by encouraging accessible, sustainable practices for cognitive health preservation," concluded the research team led by Liangkai Chen, an associate professor at Tongji Medical College at the Huazhong University of Science and Technology in Wuhan, China. MRI brain scans showed that cycling also was associated with a larger hippocampus, a part of the brain involved in memory formation and learning, researchers noted. However, cycling's benefits appeared to extend mostly to people without a genetic risk for Alzheimer's, results showed. People without the APOE E4 genetic variant had a 26% lower risk of dementia and 25% lower risk of Alzheimer's. Results were not statistically significant among APOE E4 carriers, but indicated less protection from cycling. Interestingly, the results also indicate that driving offered some protection against dementia compared to taking the bus or subway. "Even when using inactive travel like car or public transportation, it seemed like driving had a little bit better impact [on brain health] than public transportation," Sinvani said in the news release. However, researchers noted that this observational study could not draw a direct cause-and-effect link between cycling and healthy brain aging. "What I tell my patients and family and friends whenever they ask me what they can do to reduce their risk of dementia, is whatever gets you outside doing stuff is what you should be doing," she said. "I think we see that it's not just the physical activity, but it's also in the balance, and it really engages different parts of your brain." If you're able to get on a bike, Sinvani said, do that. If you're aren't, use your feet. "I think if it's, 'should I walk or take a bike?' I would say take a bike, but if it's 'should I walk or just stay home?' I would say definitely walk," she said. More information The U.S. Centers for Disease Control and Prevention has more on how physical activity boosts brain health. Copyright © 2025 HealthDay. All rights reserved.
UPI
3 hours ago
- UPI
Biking might help lower risk of dementia
In a new study, biking regularly for transportation appeared to lower risk of dementia by 19% and Alzheimer's disease by 22%. Photo by Adobe Stock/goodluz/HealthDay News Want to reduce your risk of dementia and Alzheimer's disease? Get on your bike and ride, a new study recommends. Biking regularly for transportation appears to lower risk of dementia by 19% and Alzheimer's by 22%, according to results published Tuesday in JAMA Network Open. The results also suggest that cycling might even help increase the size of a brain region important for memory, researchers noted. "Cycling is a moderate- to high-intensity workout, and also requires balance," said Dr. Liron Sinvani, director of geriatric services at Northwell Health in Manhasset, N.Y., who reviewed the findings. "It requires more complex brain function than walking, which is why maybe it was a better reducer of dementia risk." "It's not about just doing exercise and making that part of your routine, but thinking about the way you live your life," she added in a news release. "So instead of having to drive somewhere, taking that bike and using active travel modes to get around as part of your lifestyle becomes very important." For the study, researchers analyzed data on nearly 480,000 people participating in the UK Biobank, a long-term health study of people living in England, Scotland and Wales. As part of the study, participants noted the forms of transport they used most often to get about, not including travel to and from work. During an average follow-up of 13 years, more than 8,800 participants developed dementia and nearly 4,000 developed Alzheimer's. Results showed a lower risk for dementia and Alzheimer's among those who cycled or included cycling among other forms of travel like walking, driving or using public transportation. "Our findings suggest that promoting active travel strategies, particularly cycling, may be associated with lower dementia risk among middle-aged and older adults, which carries substantial public health benefits by encouraging accessible, sustainable practices for cognitive health preservation," concluded the research team led by Liangkai Chen, an associate professor at Tongji Medical College at the Huazhong University of Science and Technology in Wuhan, China. MRI brain scans showed that cycling also was associated with a larger hippocampus, a part of the brain involved in memory formation and learning, researchers noted. However, cycling's benefits appeared to extend mostly to people without a genetic risk for Alzheimer's, results showed. People without the APOE E4 genetic variant had a 26% lower risk of dementia and 25% lower risk of Alzheimer's. Results were not statistically significant among APOE E4 carriers, but indicated less protection from cycling. Interestingly, the results also indicate that driving offered some protection against dementia compared to taking the bus or subway. "Even when using inactive travel like car or public transportation, it seemed like driving had a little bit better impact [on brain health] than public transportation," Sinvani said in the news release. However, researchers noted that this observational study could not draw a direct cause-and-effect link between cycling and healthy brain aging. "What I tell my patients and family and friends whenever they ask me what they can do to reduce their risk of dementia, is whatever gets you outside doing stuff is what you should be doing," she said. "I think we see that it's not just the physical activity, but it's also in the balance, and it really engages different parts of your brain." If you're able to get on a bike, Sinvani said, do that. If you're aren't, use your feet. "I think if it's, 'should I walk or take a bike?' I would say take a bike, but if it's 'should I walk or just stay home?' I would say definitely walk," she said. More information The U.S. Centers for Disease Control and Prevention has more on how physical activity boosts brain health. Copyright © 2025 HealthDay. All rights reserved.
Gizmodo
4 hours ago
- Gizmodo
Solar Orbiter Captures First Clear Views of Sun's South Pole—and It's a Hot Mess
For more than 60 years, various spacecraft and telescopes have journeyed through space to stare at the Sun, capturing haunting images of the giant ball of hot gas at the heart of our solar system. Our view of the star is limited, however, by Earth's orbital plane, which allows us to observe the Sun's equator head-on while its polar regions remain in a frustrating blind spot. Solar Orbiter is now the first to image the poles from outside the ecliptic plane, offering a rare look at its chaotic magnetic field. On Wednesday, the European Space Agency (ESA) released the first clear images of the Sun's south pole, revealing that both north and south magnetic polarities are currently present on the same side. The new images will help scientists better understand the Sun's 11-year magnetic cycle and what governs its solar outbursts that sometimes result in geomagnetic storms on Earth. Solar Orbiter used momentum from its flyby of Venus on February 18 to push itself out of the ecliptic plane that contains Earth's orbit around the Sun. Around a month later, the spacecraft was able to view the star from an angle of 17 degrees below the solar equator, just enough to get a good view of the Sun's south pole for the first time. 'We didn't know what exactly to expect from these first observations – the Sun's poles are literally terra incognita,' Sami Solanki, who leads Solar Orbiter's Polarimetric and Helioseismic Imager instrument team from the Max Planck Institute for Solar System Research in Germany, said in a statement. The science team used three instruments aboard Solar Orbiter to capture images of the Sun between March 16 and 17. Each instrument observes the Sun in a different way; the Polarimetric and Helioseismic Imager (PHI) captures the Sun in visible light, the Extreme Ultraviolet Imager (EUI) images it in ultraviolet, and the Spectral Imaging of the Coronal Environment (SPICE) instrument detects light emitted by charged gas above the Sun's surface. By combining the viewing powers of all three instruments, scientists observed the Sun's south pole in turmoil. Normally, each polar region has its own magnetic field characteristics. As the Sun reaches a period of solar maximum during its 11-year cycle, its magnetic polarity flips, with the north and south magnetic poles reversing. During Solar Orbiter's observations of the Sun, the polarity from the north and the south poles are both present in the south pole. This marks a crucial time in understanding the Sun's activity. After the magnetic field flips, a single polarity slowly builds up in the Sun's poles and takes over. When the Sun reaches its solar minimum in about five to six years, the north and south poles will each have their own magnetic polarity. 'How exactly this build-up occurs is still not fully understood, so Solar Orbiter has reached high latitudes at just the right time to follow the whole process from its unique and advantageous perspective,' Solanki said. The scientists behind the mission used SPICE to measure how clumps of solar material move across the Sun's surface. Using the Doppler effect, which describes changes in frequency of light or sound as it moves away or toward the source, the team created a velocity map showing how the material's speed varies between the Sun's poles and equatorial region. With the help of Solar Orbiter, scientists will gain a better understanding of why solar wind travels faster at the poles than it does at the Sun's equator. Solar Orbiter is just getting started. The recent observations are the first set of images captured from the spacecraft's newly inclined orbit, but the spacecraft is gearing up for another Venus flyby on December 24, 2026, which will further tilt its orbit to 23 degrees below the equator to get an even better view of the Sun's poles. 'This is just the first step of Solar Orbiter's 'stairway to heaven': in the coming years, the spacecraft will climb further out of the ecliptic plane for ever better views of the Sun's polar regions,' Daniel Müller, ESA's Solar Orbiter project scientist, said in a statement. 'These data will transform our understanding of the Sun's magnetic field, the solar wind, and solar activity.'
